TriangleAdaptive Stereotactic Body Radiation (NCT05880667)
Adaptive Stereotactic Body Radiation trial for Abdominopelvic Metastases (NCT05880667). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for metastatic cancer in the abdomen or pelvis that needs local control or palliation, in adults.
The idea: use adaptive stereotactic body radiation, a precisely targeted radiation. Adapting the plan is meant to allow higher doses, 8, 9 or 10 gray per treatment, while keeping serious side effects at or below ten percent.
This phase 1 study plans 30 patients and looks for the maximum tolerated dose. At Fox Chase Cancer Center in Philadelphia, Joshua Meyer leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.